Cargando…

Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature

Detalles Bibliográficos
Autor principal:	Sepulveda-Falla, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236817/ https://www.ncbi.nlm.nih.gov/pubmed/37264439 http://dx.doi.org/10.1186/s13024-023-00626-3

Ejemplares similares

Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease
por: Kalaria, Rajesh N., et al.
Publicado: (2021)

Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer's disease
por: Montecinos-Oliva, Carla, et al.
Publicado: (2015)

APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
por: Bu, Guojun
Publicado: (2022)

Protein Predictive Modeling and Simulation of Mutations of Presenilin-1 Familial Alzheimer’s Disease on the Orthosteric Site
por: Soto-Ospina, Alejandro, et al.
Publicado: (2021)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

A general neurologist's perspective on the urgent need to apply resilience thinking to the prevention and treatment of Alzheimer's disease
por: Pomorska, Grazyna, et al.
Publicado: (2017)

SIGMAR1 Confers Innate Resilience against Neurodegeneration
por: Couly, Simon, et al.
Publicado: (2023)

Perspective: lessons learned from the COVID-19 pandemic concerning the resilience of the population
por: Adini, Bruria, et al.
Publicado: (2023)

Protection against neurodegenerative disease on Earth and in space
por: Takamatsu, Yoshiki, et al.
Publicado: (2016)

The brain compensatory mechanisms and Alzheimer's disease progression: a new protective strategy
por: Bobkova, Natalia, et al.
Publicado: (2015)

Direct oral anticoagulants: a new therapy against Alzheimer’s disease?
por: Grossmann, Klaus
Publicado: (2021)

A protective mutation against Alzheimer disease?
por: Proft, Juliane, et al.
Publicado: (2012)

It is unclear how important CRISPR-Cas systems are for protecting natural populations of bacteria against infections by mobile genetic elements
por: Westra, Edze R., et al.
Publicado: (2020)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Brain insulin resistance: an early risk factor for Alzheimer's disease development in Down syndrome
por: Barone, Eugenio
Publicado: (2021)

Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease
por: Norins, Leslie C.
Publicado: (2021)

Imaging tau pathology in Alzheimer’s disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies
por: Moscoso, Alexis, et al.
Publicado: (2022)

Learning from natural variation across the proteomes of single cells
por: Slavov, Nikolai
Publicado: (2022)

Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias
por: Yin, Zheng, et al.
Publicado: (2022)

Functional hyperconnectivity related to brain disease: maladaptive process or element of resilience?
por: Aswendt, Markus, et al.
Publicado: (2022)

Building resilient and responsive research collaborations to tackle antimicrobial resistance—Lessons learnt from India, South Africa, and UK
por: Veepanattu, P., et al.
Publicado: (2020)

Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial
por: Forrest, Jamie I., et al.
Publicado: (2022)

Endocannabinoid metabolism and Alzheimer's disease
por: Chen, Chu
Publicado: (2022)

OxInflammation in Alzheimer’s disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Resurrection and resilience of the rarest butterflies
por: Haddad, Nick M.
Publicado: (2018)

COVID, resilience, and the built environment
por: Keenan, Jesse M.
Publicado: (2020)

Natural compounds based chemotherapeutic against Chagas disease and leishmaniasis: mitochondrion as a strategic target
por: Lazarin-Bidóia, Danielle, et al.
Publicado: (2022)

Protection against Prenatal Alcohol-Induced Damage
por: Spong, Catherine Y
Publicado: (2006)

Does α (+)-Thalassaemia Protect against Malaria?
por: Pasvol, Geoffrey
Publicado: (2006)

Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
por: Szaruga, Maria, et al.
Publicado: (2015)

Predation and selection for antibiotic resistance in natural environments
por: Leisner, Jørgen J., et al.
Publicado: (2016)

Does the natural product, honokiol, have value in the battle against osimertinib resistance?
por: Vallega, Karin A., et al.
Publicado: (2020)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

The pathway to secondary prevention of Alzheimer's disease
por: McDade, Eric, et al.
Publicado: (2020)

Probiotics, prebiotics and their role in Alzheimer’s disease
por: D'Argenio, Valeria, et al.
Publicado: (2021)

Alzheimer’s Disease is a Disorder of Consciousness
por: Yokoi, Teruo
Publicado: (2023)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

Reevaluating the cause of laminopathy in Alzheimer’s disease
por: Islam, Md Imamul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o55ph0g1n44p584ehuefv0tof1